Addendum
Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11
Report documents
-
Addendum
Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11
Dossier assessment
Indication:
Adults with symptomatic chronic heart failure with left ventricular ejection fraction > 40%
Result of dossier assessment:
Unchanged after addendum
- Without type 2 diabetes mellitus (T2DM) and without chronic kidney disease (CKD) or with/without T2DM and with CKD: hint of non-quantifiable added benefit
- with T2DM and without CKD: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.
Project details
- Project no.
- A23-71
- Commission
- Commission awarded on 11.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Heart and circulation
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed